Multiple Sclerosis

The advent of increasingly efficacious disease-modifying treatments (DMTs) for multiple sclerosis (MS) has undoubtedly altered its natural history. While by now we know that an early start of DMTs, as promoted by the most recent diagnostic …

Multiple sclerosis (MS) is an autoimmune inflammation-mediated demyelinating disease of the central nervous system (CNS). The incidence rate of MS has increased in recent years and has become an essential cause of nontraumatic disability in young …

Many biological markers have been explored in multiple sclerosis (MS) to better quantify disease burden and better evaluate response to treatments, beyond clinical and MRI data. Among these, neurofilament light chain (Nf-L), although non-specific …

One of the disabling neurological diseases is multiple sclerosis (MS), characterized by demyelinating lesions in the central nervous system (CNS), with increasing incidence, and prevalence globally [ 1 ]. MS has economic, personal, and social …

It is unknown whether the currently known risk factors of multiple sclerosis reflect the etiology of progressive-onset multiple sclerosis (POMS) as observational studies rarely included analysis by type of onset. We designed a case–control study …

The prevalence of stress in people living with multiple sclerosis (plwMS) is higher than the general population [ 1 ], with elevated levels of stress reported in ~ 48% of people with relapsing–remitting MS (RRMS) [ 2 ]. Psychological stress …

Multiple sclerosis (MS) is a chronic, inflammatory, and degenerative disorder of the central nervous system that can lead to permanent and progressive neurological disability. Nearly one million people in the US are affected by MS, with a total …

Natalizumab (NAT, Biogen Idec Inc, Cambridge, Massachusetts, USA) is a monoclonal antibody that was approved in 2004 for the treatment of active relapsing–remitting multiple sclerosis (MS) [ 1 ]. NAT blocks the alpha4-beta1 integrin receptor on …